Korean drug maker Celltrion has announced that it ready to begin phase 1 and phase 3 clinical trials for CT-P17, a proposed adalimumab biosimilar referencing AbbVie’s Humira, which is used to treat a variety inflammatory diseases. The trials will be conducted simultaneously at 75 sites in 8 nations in the European region including the United Kingdom, and the company indicates that the trials will be completed by 2020.
Korean drug maker Celltrion has announced that it ready to begin phase 1 and phase 3 clinical trials for CT-P17, a proposed adalimumab biosimilar referencing AbbVie’s Humira, which is used to treat a variety inflammatory diseases. The trials will be conducted simultaneously at 75 sites in 8 nations in the European region including the United Kingdom, and the company indicates that the trials will be completed by 2020.
According to the biosimilar developer, the proposed product contains a higher-concentration formulation of adalimumab than other biosimilars that are currently approved, a fact that Celltrion hopes will differentiate its product from competitive biosimilars.
Novel formulations of biosimilars are becoming a hallmark of Celltrion’s approach; recently, the company announced that a new formulation of its infliximab biosimilar (sold as Inflectra in the United States and as Remsima in the European Union) that is intended for subcutaneous rather than intravenous administration has comparable efficacy and safety to the currently authorized product in patients with Crohn disease and rheumatoid arthritis.
Click here to read more about subcutaneous Inflectra.
If eventually approved, Celltrion’s product will compete with a growing field of biosimilars referencing the blockbuster Humira; already approved for marketing in the European Union are Amgen’s Amgevita (a molecule also authorized under the brand name Solymbic), Boehringer Ingelheim’s Cyltezo, Samsung Bioepis’ Imraldi, and Sandoz’s Hyrimoz.
The first biosimilar adalimumab products, Imraldi and Amgevita, are expected to launch in the European Union in October 2018, and national health systems, including the United Kingdom’s NHS, are already preparing to begin using the products.
In the United States, the FDA has approved 2 biosimilar adalimumab products (Cyltezo and Amgen’s Amjevita, which is given a slightly altered spelling for the US market), but no biosimilar adalimumab is set to launch prior to 2023 as a result of legal settlements concerning AbbVie’s patents on the reference product.
Celltrion also reports that its pipeline contains biosimilar candidates of bevacizumab, etanercept, cetuximab, and palivizumab, as well as innovator antibodies targeting influenza, breast cancer, hepatitis B, and rabies.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.